- Home
- UNCY vs ADAP Comparison
UNCY vs ADAP Comparison
Compare UNCY & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- ADAP
- Stock Information
- Founded
- UNCY 2016
- ADAP 2008
- Country
- UNCY United States
- ADAP United Kingdom
- Employees
- UNCY N/A
- ADAP N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- ADAP Health Care
- Exchange
- UNCY Nasdaq
- ADAP Nasdaq
- Market Cap
- UNCY 91.0M
- ADAP 75.5M
- IPO Year
- UNCY 2021
- ADAP 2015
- Fundamental
- Price
- UNCY $6.34
- ADAP $0.25
- Analyst Decision
- UNCY Strong Buy
- ADAP Buy
- Analyst Count
- UNCY 4
- ADAP 6
- Target Price
- UNCY $6.38
- ADAP $1.52
- AVG Volume (30 Days)
- UNCY 867.0K
- ADAP 595.5K
- Earning Date
- UNCY 08-13-2025
- ADAP 08-11-2025
- Dividend Yield
- UNCY N/A
- ADAP N/A
- EPS Growth
- UNCY N/A
- ADAP N/A
- EPS
- UNCY N/A
- ADAP N/A
- Revenue
- UNCY N/A
- ADAP $179,639,000.00
- Revenue This Year
- UNCY N/A
- ADAP N/A
- Revenue Next Year
- UNCY $1,458.53
- ADAP $35.48
- P/E Ratio
- UNCY N/A
- ADAP N/A
- Revenue Growth
- UNCY N/A
- ADAP 878.53
- 52 Week Low
- UNCY $2.02
- ADAP $0.20
- 52 Week High
- UNCY $11.00
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- UNCY 48.29
- ADAP 42.09
- Support Level
- UNCY $4.70
- ADAP $0.24
- Resistance Level
- UNCY $7.58
- ADAP $0.27
- Average True Range (ATR)
- UNCY 1.20
- ADAP 0.02
- MACD
- UNCY -0.07
- ADAP -0.00
- Stochastic Oscillator
- UNCY 26.03
- ADAP 23.57
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.